La Jolla Pharmaceutical (LJPC) Director Laura L. Douglass Sells 10,000 Shares

La Jolla Pharmaceutical (NASDAQ:LJPC) Director Laura L. Douglass sold 10,000 shares of the firm’s stock in a transaction on Friday, December 29th. The shares were sold at an average price of $32.32, for a total value of $323,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

La Jolla Pharmaceutical (LJPC) traded up $0.68 during trading on Wednesday, reaching $33.85. The company had a trading volume of 409,334 shares, compared to its average volume of 594,634. The stock has a market cap of $749.62, a PE ratio of -6.64 and a beta of 1.63. La Jolla Pharmaceutical has a 1 year low of $16.71 and a 1 year high of $39.28.

La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported ($1.19) EPS for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.05. equities analysts expect that La Jolla Pharmaceutical will post -4.91 EPS for the current fiscal year.

A number of research analysts have recently weighed in on the company. Cowen restated a “buy” rating and issued a $55.00 price target on shares of La Jolla Pharmaceutical in a research report on Friday, October 27th. ValuEngine upgraded La Jolla Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 26th. SunTrust Banks set a $65.00 price target on La Jolla Pharmaceutical and gave the company a “buy” rating in a research report on Thursday, December 28th. Zacks Investment Research upgraded La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a research report on Wednesday, November 1st. Finally, Jefferies Group restated a “buy” rating and issued a $40.00 price target on shares of La Jolla Pharmaceutical in a research report on Tuesday, October 3rd. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $57.14.

Institutional investors have recently bought and sold shares of the stock. Legal & General Group Plc increased its position in La Jolla Pharmaceutical by 11.6% during the 2nd quarter. Legal & General Group Plc now owns 4,456 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 462 shares in the last quarter. Jane Street Group LLC purchased a new stake in La Jolla Pharmaceutical during the 3rd quarter worth about $200,000. Trexquant Investment LP purchased a new stake in La Jolla Pharmaceutical during the 3rd quarter worth about $217,000. Voya Investment Management LLC purchased a new stake in La Jolla Pharmaceutical during the 2nd quarter worth about $243,000. Finally, GSA Capital Partners LLP purchased a new stake in La Jolla Pharmaceutical during the 3rd quarter worth about $309,000.

ILLEGAL ACTIVITY WARNING: This news story was first published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2018/01/03/la-jolla-pharmaceutical-ljpc-director-laura-l-douglass-sells-10000-shares.html.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).

Insider Buying and Selling by Quarter for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply